Riding to work turns travel time into training time. That is why busy cyclists stick with it. One honest caveat: the big numbers come from cohort studies, not trials, so committed riders may simply have been healthier to begin with. Even read cautiously, the pattern holds.
In the UK Biobank, 263,450 middle-aged adults reported how they travelled to work and were followed for around five years. The cyclists did better across the board. Compared with car and public transport, their risks ran lower for all-cause death (hazard ratio 0.59, 95% CI 0.42 to 0.83), cardiovascular events (0.54), cancer diagnoses (0.55) and cancer deaths (0.60). Commutes that included some cycling showed smaller benefits, and walking-only commutes improved heart outcomes without clearly moving death or cancer risk. A separate cohort of 80,306 British adults found a smaller mortality benefit for regular cyclists (hazard ratio 0.85). These are associations in self-selected riders, which is precisely why this grades moderate rather than strong.
Doing it: Ride whatever you can sustain week after week. Two or three commuting trips already add up, and a partial bike leg inside an otherwise sedentary commute still showed benefit in the data. Spend on lights before you spend on the frame.
Who it suits: Anyone with a plausible route. It suits people who cannot justify dedicated workout time, and the low impact makes it kinder to knees than running.
Sources
- Celis-Morales et al., BMJ 2017; active commuting and incident cardiovascular disease, cancer, and mortality, prospective cohort (PMID 28424154)
- Oja et al., British Journal of Sports Medicine 2017; specific sports and mortality, cohort of 80,306 British adults (PMID 27895075)
Next in exercise: Exercise for brain health →
Prefer to start with what a blood test can tell you? All 48 diagnostic tests, ranked →